|
|
|
Volumn 10 Suppl 1, Issue , 2003, Pages 23-28
|
|
Cardiovascular safety of PDE5 inhibitors.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PHOSPHODIESTERASE INHIBITOR;
PIPERAZINE DERIVATIVE;
SILDENAFIL;
AGED;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL;
COMORBIDITY;
CONTROLLED CLINICAL TRIAL;
DOSE RESPONSE;
FOLLOW UP;
HEART INFARCTION;
HUMAN;
IMPOTENCE;
MALE;
MIDDLE AGED;
ORAL DRUG ADMINISTRATION;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
RISK ASSESSMENT;
RISK FACTOR;
SURVIVAL RATE;
ADMINISTRATION, ORAL;
AGED;
CARDIOVASCULAR DISEASES;
COMORBIDITY;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FOLLOW-UP STUDIES;
HUMANS;
IMPOTENCE;
MALE;
MIDDLE AGED;
MYOCARDIAL INFARCTION;
PHOSPHODIESTERASE INHIBITORS;
PIPERAZINES;
RANDOMIZED CONTROLLED TRIALS;
RISK ASSESSMENT;
RISK FACTORS;
SURVIVAL RATE;
|
|
EID: 0037529063
PISSN: 11959479
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (8)
|
|
References (15)
|
